Ozempic, Wegovy, Semaglutides: What You Need to Know BEFORE You Get Pregnant - Dr Lora Shahine

Planning Pregnancy While on Semaglutide: Dr. Shahine's Clinical Guidance

Dr. Lora Shahine returns with a more focused video on what women need to know about semaglutide and pregnancy planning. While her earlier video on Ozempic babies covered the surprise pregnancy angle, this one is aimed at women who are intentionally planning to conceive and want to understand how semaglutide fits into that timeline. With 26,000 views, it has clearly found an audience of women navigating this exact decision. Dr. Shahine's approach is practical and clinical: she walks through the current evidence, the recommended protocols, and the gray areas where we simply do not have enough data yet.

The foundational advice is straightforward. Semaglutide should be stopped before conception. The drug has not been studied in pregnant women, and animal studies showed adverse fetal outcomes at high doses. That does not mean it is definitively harmful to human pregnancies, but it means we do not know, and the precautionary principle applies. Dr. Shahine recommends stopping semaglutide at least two months before attempting conception to allow the drug to clear your system. Given semaglutide's half-life of approximately one week, two months provides a generous washout period.

The Weight Regain Concern

One of the most important topics Dr. Shahine addresses is weight regain after stopping semaglutide. This is a real and common concern. Many women worry that if they stop their GLP-1 medication to get pregnant, they will regain the weight they lost, and that the metabolic improvements that helped them become fertility candidates will reverse. Dr. Shahine acknowledges this concern honestly. Weight regain after stopping GLP-1 drugs is well-documented, and it can happen quickly. Her advice is to use the washout period to establish strong dietary and exercise habits that can partially buffer against regain, and to work with your medical team to monitor your metabolic markers during the transition.

The timing consideration is also relevant for women using GLP-1 drugs as part of a pre-IVF optimization plan. Some reproductive endocrinologists are prescribing short courses of semaglutide to help patients lose weight and improve insulin sensitivity before starting IVF. In these cases, the timeline needs to account for the drug washout, the potential for partial weight regain, and the IVF cycle timeline. Dr. Shahine notes that close coordination between your prescriber and your fertility doctor is essential, since these two clinicians may not be the same person and they need to be communicating about the overall plan.

What the Video Gets Right

Dr. Shahine is clear-eyed about both the benefits and the limitations of what we know. She accurately represents the current evidence base, which is largely observational rather than from randomized controlled trials. She correctly identifies the two-month washout recommendation and explains why it exists. She also makes the important point that the decision to stop semaglutide before pregnancy is about more than the drug itself but about creating the healthiest possible metabolic environment for conception and early pregnancy.

What the Video Misses

The video does not address what happens if a woman accidentally becomes pregnant while still on semaglutide. This is a real scenario, especially given the improved fertility that comes with weight loss and the birth control interaction discussed in other videos. Women in this situation need guidance on whether to stop the drug immediately, what monitoring their OB should do, and what the actual risk level is based on available data. The video also does not discuss breastfeeding, which is another period where semaglutide use is not recommended due to lack of data. For a full pregnancy planning picture, the postpartum medication timeline matters too.

Questions to Bring to Your Doctor

Before your next fertility or preconception appointment, prepare these questions. What is the recommended washout period for the specific GLP-1 drug I am taking? How should I manage my nutrition and exercise during the washout period to minimize weight regain? If I am doing IVF, how does the semaglutide washout fit into the cycle timeline? What metabolic markers should we monitor during the transition off the medication? And if I get pregnant unexpectedly before completing the washout period, what is the protocol?

The Evidence Gap: What We Do and Do Not Know

It is worth being explicit about what the evidence base actually looks like for semaglutide and pregnancy outcomes. The animal data that drives the precautionary recommendation comes from studies in rats and rabbits exposed to semaglutide during gestation. These studies showed increased rates of structural abnormalities and pregnancy loss at doses that produced clinically relevant drug exposure levels. However, animal reproductive toxicity studies do not always predict human outcomes accurately, and the doses used in animal studies are often higher relative to body weight than the doses prescribed in clinical practice for human patients.

The human data is extremely limited because pregnant women are systematically excluded from clinical trials for obvious ethical reasons. What exists comes from pregnancy registries and case reports of women who became pregnant while on semaglutide, either intentionally or accidentally. These reports have not shown a clear signal of increased birth defects or adverse pregnancy outcomes compared to the general population rate, but the numbers are small and the data is observational rather than from controlled studies. A pregnancy registry for semaglutide exists and is actively collecting data, but it will be years before enough cases accumulate to draw meaningful statistical conclusions about the drug safety profile during human pregnancy.

This evidence gap creates real anxiety for women who are trying to make informed decisions about their treatment timeline. The precautionary recommendation to stop semaglutide two months before conception is reasonable given the uncertainty, but it requires accepting a period of potential weight regain during a time when you are also dealing with the stress and excitement of trying to conceive. Some women find this trade-off acceptable and manageable. Others struggle with the idea of losing the metabolic support that the drug provides precisely when they are trying to create the healthiest possible conditions for pregnancy and embryonic development.

For women who accidentally become pregnant while still on semaglutide, which is a real and increasingly common scenario given the improved fertility and birth control interactions, the general guidance is to stop the medication immediately and contact your OB-GYN. The existing case reports are reassuring in that they have not identified a consistent pattern of adverse outcomes in these situations, but your doctor will want to monitor the pregnancy more closely with additional ultrasound screening. The most important message is to not panic. Accidental drug exposure during early pregnancy is common across many medication categories, and the outcome is usually normal. But prompt communication with your medical team ensures that appropriate monitoring is in place from the earliest stages of pregnancy.

Who Should Watch This

This video is targeted directly at women who are currently on semaglutide and planning to get pregnant in the near future. If that is your situation, this is one of the most relevant videos available on the topic. It is also useful for women who are in the early stages of fertility treatment and whose doctor has suggested weight loss as a preparatory step. Partners who want to understand the treatment timeline will also find it informative. The video is less relevant for women who are not planning pregnancy or who are past reproductive age, though the information about drug washout periods applies broadly to anyone considering stopping a GLP-1 medication for any reason.

Planning pregnancy while managing a GLP-1 medication requires coordination, timing, and honest conversations with your medical team. Dr. Shahine provides a solid framework for thinking through the decisions, even as the evidence base continues to develop.

The breastfeeding question is a natural extension of the pregnancy planning discussion, and it deserves mention even though the video focuses on the preconception period. Current recommendations advise against using semaglutide while breastfeeding because there is no human data on whether the drug passes into breast milk in significant quantities or affects the nursing infant. Animal data shows semaglutide in the milk of lactating rats, but translating animal lactation data to humans is unreliable. For women planning to breastfeed, this means the total time off semaglutide includes the washout period before conception, the entire pregnancy, and the duration of breastfeeding, which could be 18-24 months or longer in total. Planning for this extended medication break and having weight management strategies in place for the entire period is part of thorough pregnancy planning that Dr. Shahine touches on but could explore more thoroughly.

The good news is that the metabolic improvements from pre-pregnancy weight loss tend to persist through pregnancy and lactation to some degree, even without the medication. Women who enter pregnancy at a healthier weight and with better insulin sensitivity have lower rates of gestational diabetes, preeclampsia, and other pregnancy complications. The investment in GLP-1-assisted preconception health optimization pays dividends throughout the pregnancy even after the drug has been stopped. This is part of the rationale for using these drugs before pregnancy rather than wishing you could use them during or after: the benefits of a healthier metabolic starting point compound throughout the reproductive journey.